Xencor (XNCR) Capital Expenditures (2013 - 2026)
Xencor (XNCR) posted quarterly Capital Expenditures of $610000.0 for Q1 2026, down 57.76% year-over-year from $1.4 million in Q1 2025, and down 46.49% quarter-over-quarter from $1.1 million in Q4 2025.
Xencor (XNCR) Capital Expenditures (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Capital Expenditures for 14 consecutive years, with $610000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 57.76% year-over-year to $610000.0; the TTM figure through Mar 2026 stood at $2.3 million (down 68.74% YoY), while the FY2025 annual figure was $3.2 million, down 48.34% from the prior year.
- Capital Expenditures fell to $610000.0 in Q1 2026 per XNCR's latest filing, from $1.1 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $14.1 million in Q3 2022 and bottomed at $132000.0 in Q1 2024.
- Historically, Capital Expenditures has averaged $3.9 million across 5 years, with a median of $1.7 million in 2024.
- Annual changes were most pronounced in 2024 — Capital Expenditures slumped 98.78% — and 2025, when it jumped 993.94%.
- Xencor's Capital Expenditures stood at $10.0 million in 2022, then plunged by 90.17% to $980000.0 in 2023, then surged by 69.8% to $1.7 million in 2024, then tumbled by 31.49% to $1.1 million in 2025, then plunged by 46.49% to $610000.0 in 2026.
- Business Quant data shows XNCR's Capital Expenditures at $610000.0 in Q1 2026, $1.1 million in Q4 2025, and $183000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 538,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 538,000.00 |
| Jun 30, 2026 | 538,000.00 |
| Mar 31, 2026 | 610,000.00 |
| Mar 31, 2026 | 610,000.00 |
| Dec 31, 2025 | 1.14 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 183,000.00 |
| Sep 30, 2025 | 183,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Mar 31, 2025 | 1.44 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Mar 31, 2024 | 132,000.00 |
| Mar 31, 2024 | 132,000.00 |